The market for spinal cord stimulation just saw a significant boost, with Saluda Medical securing $150.0M in a Series e funding round. The company is known for its Evoke® System, which stands out as the world’s first ECAP-controlled, closed-loop SCS therapy.
This innovative system delivers personalized, data-driven therapy by automatically adjusting stimulation over four million times daily, based on real-time neural signals unique to each patient. Saluda Medical aims to empower clinicians to precisely measure and prescribe optimal stimulation, improving consistency and patient outcomes for chronic intractable pain.
